Agenda:
Thursday 22 June 2006
08.00
Registration
09.15
THEATRE
Chairman's Opening Welcome:
Anthony Warnock-Smith, Partner European Life Sciences, Morgan Lewis
09.30
Panel Discussion:
The changing Pharma - Biotech interface
Chair: Stephanie Léouzon, Managing Director, European Healthcare, Credit Suisse First Boston
Panellists: Kenneth D Noonan, Ph.D., Partner, L.E.K. Consulting
Genghis Lloyd-Harris, MD, Ph.D., Partner, Abingworth Management
Tamar Howson, Senior Vice President, Corporate Development, Bristol-Myers Squibb
Dr Axel Polack, Venture Partner, TVM Capital
10.40
Coffee Break
11.10-12.20
Small-Cap Listed Company Presentations
ROOM: THEATRE
Chair: Dimitri Dimitriou, DyoDelta Biosciences		 ROOM: FORUM
Chair: Peter Kalinka, Accelsiors Group
11.15
Dr Steven Powell,
Chief Executive Officer,
Plethora Solutions		 Dr Dai Chaplin,
Head of Research & Development,
Oxigene
11.30
Simon Kerr,
Commercial Director,
CeNeS Pharmaceuticals		 Dr Ulrich Dauer,
Chief Executive Officer,
4SC
11.45
Dr Paul Ashton,
Director of Strategy,
pSivida		 Dr Fahar Merchant,
President & CEO,
Protox Therapeutics
12.00
Tom Williams,
Chief Executive Officer,
Bio Diem 		Michael Hunt,
Chief Executive Officer,
ReNeuron
12.15
Questions to panellists Questions to panellists
12.30
Lunch
13.45
Capital Finance Panel
Chair: Anthony Warnock-Smith, Partner European Life Sciences, Morgan Lewis
Panellists: Nessan Bermingham, Principal, Atlas Venture
Andrew Wallace, UK Main Market Product Manager, London Stock Exchange
Dr Brian Hargreaves, Sector Partner – Healthcare, 3i
Denise Pollard-Knight, Chief Executive Officer, Nomura Phase4 Ventures
14.30-16.40
Sector Workshops: Venture Funded, Early - Mid Stage Biotech Companies
14.35
ROOM: THEATRE
Chair: Dr Chris Gardner, Citigate Dewe Rogerson 		ROOM: FORUM
Chair: Douglas Pretsell , Northbank Communications
14.40
Joerg Scheidle,
Managing Director & CFO,
immatics biotechnologies 		Nick Landekic,
President & CEO,
PolyMedix
14.55
Dr Martin Buckland,
Chief Business Officer,
Astex Therapeutics 		Dr Mark Schwartz,
President & CEO,
Bayhill Therapeutics
15.10
Dr Clive Dix,
Chief Executive Officer,
PowderMed 		Dr Kirsten Drejer ,
Chief Executive Officer,
Symphogen
15.25
Dr Bernhard Sixt ,
Chief Executive Officer,
Agendia 		Dr André Choulika ,
President & CEO,
Cellectis
15.40
Dr Keith McCullagh ,
Chief Executive Officer,
Santaris Pharma 		Dr William Garner,
Managing Director & CEO,
Inverseon
15.55
Dr Johanna Holldack ,
Chief Executive Officer,
BOREAN Pharma 		David King ,
Chief Executive Officer,
BioRexis
16.10
Dr Michael Moore ,
Chief Executive Officer,
PIramed 		Dr Paul Reid ,
Director & CSO,
Celtic Biotech
16.25
Dr Steven Burton ,
Chief Executive Officer,
ProMetic Biosciences 		Dr Robert Burns ,
Chief Executive Officer,
Celldex
16.40
Questions to Panellist and close of conference Questions to Panellist and close of conference
 

To download a pdf version of this agenda click here.

Back to top